Difference between revisions of "Glofitamab (Columvi)"
Jump to navigation
Jump to search
m |
m |
||
| Line 16: | Line 16: | ||
[[Category:Anti-CD20 BiTE antibodies]] | [[Category:Anti-CD20 BiTE antibodies]] | ||
| − | + | [[Category:Anti-CD3 BiTE antibodies]] | |
| − | [[Category:Anti-CD3 antibodies]] | ||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
Revision as of 23:51, 30 June 2023
Mechanism of action
From the NCI Drug Dictionary: A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, glofitamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.
Diseases for which it is used
History of changes in FDA indication
- 2023-06-15: Initial accelerated approval for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. (Based on NP30179)
Also known as
- Code name: RO 7082859
- Generic name: glofitamab-gxbm
- Brand name: Columvi